Kennett Sprogøe
27Patents
5h-index
35Co-inventors
65Inventor score
Filing activity: Oct 6, 2010 → Jan 24, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10980860B2 | Diagnosis, prevention and treatment of diseases of the joint | Emerging Cross-Sectional Technologies | 8 | Active |
| US11590207B2 | Dosage regimen for a controlled-release PTH compound | Human Necessities | 7 | Active |
| US9872864B2 | Sustained release composition of prostacyclin | Human Necessities | 5 | Active |
| US10960053B2 | PEGylated recombinant human growth hormone compounds | Chemistry; Metallurgy | 5 | Active |
| US10519226B2 | VEGF neutralizing prodrugs for the treatment of ocular conditions | Chemistry; Metallurgy | 5 | Active |
| US11389511B2 | Controlled-release CNP agonists with reduced side-effects | Human Necessities | 4 | Active |
| US11564974B2 | Combination therapy with controlled-release CNP agonists | Human Necessities | 4 | Active |
| US11311604B2 | Controlled-release CNP agonists with low NPR-C binding | Emerging Cross-Sectional Technologies | 4 | Active |
| US11224661B2 | Controlled-release CNP agonists with increased NEP stability | Emerging Cross-Sectional Technologies | 4 | Active |
| US11389510B2 | Controlled-release CNP agonists with low initial NPR-B activity | Emerging Cross-Sectional Technologies | 4 | Active |
| US11918628B2 | Controlled-release PTH compound | Human Necessities | 3 | Active |
| US11890326B2 | Controlled-release PTH compound | Human Necessities | 3 | Active |
| US11759504B2 | PTH compounds with low peak-to-trough ratios | Human Necessities | 3 | Active |
| US11857603B2 | PTH compounds with low peak-to-trough ratios | Human Necessities | 3 | Active |
| US11793861B2 | PTH prodrugs | Human Necessities | 3 | Active |
| US9561287B2 | Carrier-linked treprostinil prodrugs | Human Necessities | 1 | Active |
| US12083182B2 | Controlled-release CNP agonists with increased NEP stability | Emerging Cross-Sectional Technologies | 1 | Active |
| US8758780B2 | Subcutaneous paliperidone composition | Human Necessities | 0 | Active |
| US12156917B2 | CNP prodrugs with carrier attachment at the ring moiety | Human Necessities | 0 | Active |
| US12016903B2 | Long-acting growth hormone treatment | Human Necessities | 0 | Active |
| US12214020B2 | PTH prodrugs | Chemistry; Metallurgy | 0 | Active |
| US10729778B2 | Carrier-linked treprostinil prodrugs | Human Necessities | 0 | Active |
| US12303553B2 | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin | Human Necessities | 0 | Active |
| US12403182B2 | Liquid pharmaceutical formulations of PTH conjugates | Human Necessities | 0 | Active |
| US12295989B2 | Controlled-release PTH compound | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.